StockNews.com Initiates Coverage on Catalent (NYSE:CTLT)

Equities researchers at StockNews.com initiated coverage on shares of Catalent (NYSE:CTLT) in a report issued on Friday. The firm set a “sell” rating on the stock.

A number of other research analysts have also recently weighed in on CTLT. Royal Bank of Canada reiterated a “sector perform” rating and issued a $63.50 target price on shares of Catalent in a report on Tuesday, February 20th. Stephens reissued an “equal weight” rating and issued a $63.50 price objective on shares of Catalent in a research report on Thursday, April 4th. Two research analysts have rated the stock with a sell rating, seven have issued a hold rating and three have issued a buy rating to the company’s stock. According to data from MarketBeat.com, the company has a consensus rating of “Hold” and an average price target of $54.05.

Catalent Price Performance

Shares of NYSE:CTLT opened at $55.48 on Friday. The company has a debt-to-equity ratio of 1.37, a quick ratio of 1.77 and a current ratio of 2.51. The business’s fifty day moving average price is $55.66 and its two-hundred day moving average price is $52.65. The stock has a market cap of $10.04 billion, a PE ratio of -9.10, a price-to-earnings-growth ratio of 6.64 and a beta of 1.20. Catalent has a one year low of $31.80 and a one year high of $60.20.

Catalent (NYSE:CTLT) last posted its quarterly earnings data on Wednesday, May 8th. The company reported ($0.15) EPS for the quarter, missing analysts’ consensus estimates of $0.21 by ($0.36). Catalent had a negative net margin of 26.61% and a negative return on equity of 2.73%. The company had revenue of $1.07 billion for the quarter, compared to analyst estimates of $1.11 billion. On average, analysts forecast that Catalent will post 0.28 EPS for the current fiscal year.

Insider Buying and Selling

In related news, insider Ricky Hopson sold 1,401 shares of the company’s stock in a transaction that occurred on Tuesday, June 4th. The stock was sold at an average price of $54.26, for a total transaction of $76,018.26. Following the sale, the insider now directly owns 20,617 shares of the company’s stock, valued at approximately $1,118,678.42. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Insiders own 0.31% of the company’s stock.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently modified their holdings of the business. Vanguard Group Inc. lifted its position in shares of Catalent by 1.8% during the 3rd quarter. Vanguard Group Inc. now owns 20,468,027 shares of the company’s stock valued at $931,909,000 after acquiring an additional 365,648 shares during the last quarter. Tran Capital Management L.P. lifted its stake in Catalent by 12.2% in the 4th quarter. Tran Capital Management L.P. now owns 361,846 shares of the company’s stock worth $16,258,000 after acquiring an additional 39,208 shares in the last quarter. Hsbc Holdings PLC boosted its holdings in shares of Catalent by 43.1% during the third quarter. Hsbc Holdings PLC now owns 193,322 shares of the company’s stock worth $8,803,000 after purchasing an additional 58,240 shares during the period. Dimensional Fund Advisors LP increased its stake in shares of Catalent by 29.9% in the fourth quarter. Dimensional Fund Advisors LP now owns 1,639,197 shares of the company’s stock worth $73,655,000 after acquiring an additional 376,931 shares during the last quarter. Finally, SG Americas Securities LLC grew its holdings in shares of Catalent by 240.0% during the fourth quarter. SG Americas Securities LLC now owns 40,249 shares of the company’s stock worth $1,808,000 after purchasing an additional 28,410 shares during the last quarter.

About Catalent

Catalent, Inc, together with its subsidiaries, develops and manufactures solutions for drugs, protein-based biologics, cell and gene therapies, and consumer health products worldwide. It operates in two segments, Biologics, and Pharma and Consumer Health. The Biologics segment provides formulation, development, and manufacturing for biologic proteins, cell gene, and other nucleic acid therapies; pDNA, iPSCs, oncolytic viruses, and vaccines; formulation, development, and manufacturing for parenteral dose forms, including vials, prefilled syringes, and cartridges; and analytical development and testing services for large molecules.